ANARI-AI
20.4.2021 14:01:13 CEST | Business Wire | Press release
Anari AI , an AI chip factory in the cloud, today announced it has raised $2 million in seed funding led by Earlybird , with participation from Acequia Capital , Serbian Entrepreneurs , and Eric Ries , author and founder of The Lean Startup . The new funding will be used to continue developing the platform and bring it to market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005700/en/
Anari’s platform makes it possible to design personalized AI chips in the cloud with just one click. With this approach, companies are able to build and deploy AI solutions in weeks instead of 12-18 months, and at a fraction of the cost of traditional hardware development.
“AI continues to be growing in size and complexity, and this rate of growth is outpacing standard CPU and GPU performance gains,” said Roland Manger , co-founder and Partner at Earlybird. “Dedicated designs or flexible architectures are expensive, time-consuming and require hardware skills (in short: take lots of effort). Anari is a game changer in two ways: it removes the trade-off between performance and effort, and it makes AI-problem-specific chip solutions available instantaneously in the cloud. I am excited about this huge potential.”
The platform is built on a unique Python-based programming framework—developed by Anari for chip design—that opens up new possibilities for hardware engineers and turns software engineers into hardware designers. The first configurable AI cloud chip from Anari is Thor X, which delivers 100x more efficient processing of 3D Point Cloud/Graph data structures compared to a high-end GPU.
Anari’s team consists of Ph.D. researchers, machine learning experts, and senior software engineers. The team is led by Jovan Stojanovic (co-founder and CEO), Stefan Sredojevic (co-founder and COO), and Bogdan Vukobratovic (co-founder and Head of R&D). Jovan is the founder of the Wonderland AI community that includes more than 30,000 AI experts and enthusiasts from all over the world. The yearly Wonderland AI Summit gathers C-level speakers and attendees from the world’s leading AI companies like NVIDIA, Airbus, HP, IBM, Mercedes, etc.
“You no longer have to tune your model to the computing infrastructure that’s available and designed for broad and generic use cases,” said Sasha Ostojic , ex-VP at NVIDIA, ex-SVP at Cruise Automation, Advisor at Samsung Electronics and Zoox, and Operating Partner at Playground Global.“ Anari's cloud chip technology is the future of cloud computing.”
Roland Manger and Sasha Ostojic will be joining Anari's Board of Directors. Advisors to the company include Christoph Auer-Welsbach (former Partner at IBM Ventures, Founder of CITY AI, and CEO of Kaizo) and Dejan Markovic (co-founder of Flex Logix and Professor at UCLA).
“With AI model complexity doubling every three and a half months, the current way of building the AI infrastructure is not sustainable,” said Jovan Stojanovic, co-founder and CEO of Anari AI. “We believe that every company deserves to have a personalized chip for their AI in just one click. We’re supporting the rapid progress of AI in ways that haven’t been possible until now. With experienced investors like Earlybird on our side, we’re ready to rebuild the AI hardware industry from scratch.”
About Anari AI
Anari AI is rebuilding the AI hardware industry from scratch by delivering a new way of designing and using AI chips through programming in the cloud. The Anari platform for cloud chips can be used by companies across industries such as gaming, automotive and biotechnology to personalize their AI infrastructure with just one click. The company is based in Serbia and has an office in San Francisco. The global team includes advisors with experience from NVIDIA, CERN, IBM, UC Berkeley, and UCLA.
For more information, visit www.anari.ai .
About Earlybird VC
Earlybird is a venture capital investor focused on European technology companies. Founded in 1997, Earlybird invests in all growth and development phases of a company. Amongst the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources, but also strategic and operational support as well as access to an international network and capital markets.
Earlybird Venture Capital has grown to three autonomous, dedicated and specialized teams, focusing on digital technologies in Eastern and Western Europe as well as health technologies. Among them, the Digital East Fund is focused on early stage ICT investment opportunities in Eastern Europe and Turkey, being the leading tech VC in this region. With EUR 1.5 billion under management, seven IPOs and 30 trade sales, Earlybird is one of the most successful venture capital firms in Europe. Discover more at www.earlybird.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005700/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press release
The collaboration leverages Elevate Farms’ proprietary vertical farming technology reducing water consumption, land usage and carbon emissions. Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland req
SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press release
Revenue of $9.45 billion increased 5% sequentially and 6% year on year GAAP EPS of $0.49 decreased 6% sequentially and 2% year on year EPS, excluding charges and credits, of $0.64 increased 16% sequentially and decreased 7% year on year Net income attributable to SLB of $735 million decreased 6% sequentially and 1% year on year Adjusted EBITDA of $2.07 billion increased 9% sequentially and was essentially flat year on year Cash flow from operations was $1.51 billion and free cash flow was $828 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom